This article was originally published in The Tan Sheet
Executive SummaryAllegan, Mich.-based generics firm saw "strong sales of loratadine D-24, the store brand equivalent to Claritin D-24; had strong initial shipments of loratadine syrup and loratadine quick-dissolve tablets; and experienced growth in the vitamin category" during the third quarter ended March 27, Perrigo CEO David Gibbons reports in an April 23 earnings call. Overall net sales grew 14% to $230.7 mil. compared to the year-ago quarter. Results were driven by "new products launched earlier in the year, new products shipping in the current period, and revenue from Peter Black Pharmaceuticals, a UK-based nutritional business acquired in December 2003"...
You may also be interested in...
HBW Executive Decisions: Perrigo Americas, Nutraceutical International Helm Changes, ABC Farnsworth Award, More
Myos Rens hires Eric LeGrand as special advisor for sports nutrition; Perrigo Consumer Americas chief Jeff Needham will be succeeded by Rich Sorota; Nutraceutical International appoints Monty Sharma to replace Chad Clawson at the helm; American Botanical Council’s Farnsworth Award goes to Rachel Mata; and Herbalife’s John Agwunobi will be chairman as well as CEO.
Philips Expert Urges Device Makers: Update Quality Systems To Conform To Revised Risk Standard ISO 14971
It’s time for manufacturers to begin adopting the new 2019 version of ISO 14971, the international standard for risk management widely used by industry. But firms need to do more work than just changing the date on risk-related procedures and documents to “2019,” says Jos Van Vroonhoven, a senior manager at Philips Healthcare who was intimately involved with the standard’s redo. From conducting gap assessments to creating cross-functional teams, both Van Vroonhoven and longtime industry expert Don Powers tell Medtech Insight how firms can keep their quality systems up-to-date to conform to ISO 14971:2019.